UNSPSC 51442004: Fluorouracil

This classification denotes a thymidylate synthase inhibitor and pyrimidine antagonist with the molecular formula C4H3FN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U3P01618RT, chemically known as 2,4-dioxo-5-fluoropyrimidine but more generally known as fluorouracil, which bears U.S. National Institutes of Health Compound Identifier 3385. The European Medicines Agency schedules Fluorouracil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07721MIG.

UNSPSC 51442004 Fluorouracil is a Commodity code that in recent state and local solicitations does not show activity in pharmaceutical procurement aligned with the code's nominal scope. The recent opportunities tagged to this code instead reflect radiologic and X-ray equipment, X-ray system maintenance services, and chemical supplies — none of which fall within fluorouracil or oncology pharmaceutical procurement. Maricopa County solicited radiologic equipment and installation services for college facilities under IFB 362910 (due October 22, 2026); Escambia County Correction pursued extended warranty coverage for X-ray machines under sole-source procurement SSCORALM2526005 (due August 19, 2026); and Broward County Aviation issued an RFI to test sole-source designation for Rapiscan X-ray system maintenance services (due July 28, 2026). Pasco County, Florida posted an RFQ for copper sulfate crystals and liquid copper sulfate on an as-needed basis (due June 26, 2026). The issuing bodies span county purchasing offices and specialized departments (corrections, aviation) but do not reflect pharmaceutical or healthcare procurement typical of fluorouracil acquisitions.

The geographic spread of recent activity includes Florida (Escambia, Broward, Pasco counties) and Arizona (Maricopa County), though the mismatch between the code's pharmaceutical focus and the actual scope of posted solicitations suggests this code does not reliably capture state and local fluorouracil procurement. The recent opportunities reflect equipment, maintenance services, and industrial chemicals rather than oncology drugs or related pharmaceutical goods. No evidence in the source supports active fluorouracil procurement by state or local health departments, hospital systems, or correctional health services under this code.